不明原因反复种植失败后活产的预后如何
该回顾性队列随访研究纳入2008年1月至2012年12月两家三级转诊大学医院中223名39岁以下、IVF/ICSI后不明原因反复种植失败(RIF)的女性,118名数据可分析,最长随访5.5年,活产累积发生率为49%(95%CI 39-59%),中位妊娠时间9个月,18%为自然妊娠。
要点
- 不明原因RIF女性最长随访5.5年活产累积发生率为49%(95%CI 39-59%)。
- 获得活产者中位妊娠时间为诊断RIF后9个月,18%为自然妊娠。
- 本研究未发现可预测后续活产的临床因素。
核心结论
- 不明原因RIF女性总体活产预后较好,尤其是继续接受IVF/ICSI治疗者;但51%在随访期内未获活产,需区分最可能从进一步治疗中获益者。
研究设计与样本
- 回顾性队列随访研究,纳入2008年1月至2012年12月两家三级转诊大学医院中223名39岁以下、IVF/ICSI后不明原因RIF的女性,118名数据可分析。
主要发现
- 最长5.5年随访期内活产累积发生率为49%(95%CI 39-59%)。
- 获得活产者中位妊娠时间为RIF后9个月,其中18%为自然妊娠。
- 本研究未发现可预测后续活产的临床因素。
关键数值与推荐
- RIF当前定义包括IVF/ICSI后未获妊娠且经历三次或以上新鲜胚胎移植(每次移植一或两枚高质量胚胎)或移植胚胎总数超过10枚(新鲜或冻融周期)。
临床怎么用
- 作者认为不明原因RIF女性总体活产预后较好,尤其继续接受IVF/ICSI治疗者;但51%随访期内未获活产,需区分最可能从进一步治疗中获益者。
- 本研究未发现可预测后续活产的临床因素。
局限性
- 仅57%符合条件的研究队列完成问卷,应答偏倚风险限制研究发现的适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the cumulative incidence of live birth and mean time to pregnancy (by conception after IVF/ICSI or natural conception) in women experiencing unexplained recurrent implantation failure (RIF) following IVF/ICSI treatment? SUMMARY ANSWER: In 118 women who had experienced RIF, the reported cumulative incidence of live birth during a maximum of 5.5 years follow-up period was 49%, with a calculated median time to pregnancy leading to live birth of 9 months after diagnosis of RIF. WHAT IS KNOWN ALREADY: Current definitions of RIF include failure to achieve a pregnancy following IVF/ICSI and undergoing three or more fresh embryo transfer procedures of one or two high quality embryos or more than 10 embryos transferred in fresh or frozen cycles. The causes and optimal management of this distressing condition remain uncertain and a range of empirical and often expensive adjuvant therapies is often advocated. Little information is available regarding the long-term prognosis for achieving a pregnancy. STUDY DESIGN, SIZE, DURATION: Two hundred and twenty-three women under 39 years of age who had experienced RIF without a known cause after IVF/ICSI treatment in two tertiary referral university hospitals between January 2008 and December 2012 were invited to participate in this retrospective cohort follow up study. PARTICIPANTS/MATERIALS, SETTING, METHODS: All eligible women were sent a letter requesting their consent to the anonymous use of their medical file data and were asked to complete a questionnaire enquiring about treatments and pregnancies subsequent to experiencing RIF. Medical files and questionnaires were examined and results were analysed to determine the subsequent cumulative incidence of live birth and time to pregnancy within a maximum 5.5 year follow-up period using Kaplan Meier analysis. Clinical predictors for achieving a live birth were investigated using a Cox hazard model. MAIN RESULTS AND THE ROLE OF CHANCE: One hundred and twenty-seven women responded (57%) and data from 118 women (53%) were available for analysis. During the maximum 5.5 year follow up period the overall cumulative incidence of live birth was 49% (95% CI 39-59%). Among women who gave birth, the calculated median time to pregnancy was 9 months after experiencing RIF, where 18% arose from natural conceptions. LIMITATIONS, REASONS FOR CAUTION: Since only 57% of the eligible study cohort completed the questionnaire, the risk of response bias limits the applicability of the study findings. WIDER IMPLICATIONS OF THE FINDINGS: This study reports a favorable overall prognosis for achieving live birth in women who have previously experienced RIF, especially in those who continue with further IVF/ICSI treatments. However since 51% did not achieve a live birth during the follow-up period, there is a need to distinguish those most likely to benefit from further treatment. In this study, no clinical factors were found to be predictive of those achieving a subsequent live birth. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the University Medical Center Utrecht, in Utrecht and the Academic Medical Centre, in Amsterdam. NSM has received consultancy and speaking fees and research funding from Ferring, MSD, Merck Serono, Abbott, IBSA, Gedion Richter, and Clearblue. During the most recent 5-year period BCJMF has received fees or grant support from the following organizations (in alphabetic order); Actavis/Watson/Uteron, Controversies in Obstetrics & Gynecology (COGI), Dutch Heart Foundation, Dutch Medical Research Counsel (ZonMW), Euroscreen/Ogeda, Ferring, London Womens Clinic (LWC), Merck Serono, Myovant, Netherland Genomic Initiative (NGI), OvaScience, Pantharei Bioscience, PregLem/Gedeon Richter/Finox, Reproductive Biomedicine Online (RBMO), Roche, Teva, World Health Organisation (WHO).None of the authors have disclosures to make in relation to this manuscript.
引用
- Koot YEM, Hviid Saxtorph M, Goddijn M, et al. What is the prognosis for a live birth after unexplained recurrent implantation failure following IVF/ICSI? Hum Reprod. 2019. PMID: 31621857. doi:10.1093/humrep/dez120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。